📣HemaSphere's June issue is now complete!

Read about new horizons in the management of #VenousThromboembolism, a retrospective study on efficacy of treatment in #VEXAS,  a review on #NK-LGLL, and more  Have a browse📰 https://bit.ly/4l8BrOD

STAT3 突變不是 T-LGLL 專屬
它在 T-LGLL 約 30–40%，在 chronic NK-LGLL 也測得到（約 30%），甚至見於侵襲性 NK 細胞 leukemia。
因為 NK-LGLL 沒有 TCR 重排可用，克隆性判定要靠 KIR restriction 或 X 染色體去活化分析，STAT3 突變也提供佐證。
#血液專科
https://hema-2026.hsiehting.com/q/110-030

T-LGLL 與 NK-LGLL 的表型
T-LGLL（約 85%）：surface CD3+、CD8+、TCRαβ+、CD57+、CD5 dim、CD28−；CD4+ 型極少見。
Chronic NK-LGLL（約 15%）：surface CD3−（無 TCR 重排）、CD16+、CD56+、CD8+。
兩者都會造成單系或多系血球低下。
#血液專科
https://hema-2026.hsiehting.com/q/110-030

NK-LGLL is driven by chronic inflammation and cellular pathway activation, emphasizing the microenvironment's role in its pathogenesis. Recent genetic and epigenetic advances reveal new vulnerabilities, promising personalized therapies.

Read this recent Review article here 👉https://bit.ly/45OkCnD